• On 3 June 2026, Bristol Myers Squibb announced a clinical trial collaboration and supply agreement under which Arcus Biosciences will provide its investigational HIF-2a inhibitor casdatifan for new combination arms in the Phase 1/2 ROSETTA RCC-208 study in advanced renal cell carcinoma, while both parties retain rights to their respective assets in this non-exclusive deal.
• This collaboration highlights growing external interest in casdatifan as a potential component of combination regimens, expanding its clinical testing footprint alongside a PD-L1/VEGF-A bispecific antibody in a complex kidney cancer setting.
• We’ll now examine how the addition of casdatifan combination arms in Bristol Myers Squibb’s ROSETTA RCC-208 trial may reshape Arcus’s investment narrative.

Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

Arcus Biosciences Investment Narrative Recap

To own Arcus, you need to believe casdatifan can become a meaningful RCC therapy while the company manages ongoing losses and funding needs. The new Bristol Myers Squibb collaboration broadens casdatifan’s testing but does not yet change the key 2026 catalyst: pivotal go or no go decisions and Phase 3 planning for RCC. The biggest near term risk remains regulatory and clinical uncertainty around casdatifan and domvanalimab plus zimberelimab rather than this specific trial add on.

The April 20 update on Arcus’s alliance with Gilead is particularly relevant here, as it confirmed Arcus retains global rights to casdatifan outside Japan and parts of Asia. That context makes the Bristol Myers Squibb deal more meaningful, because any positive casdatifan data from ROSETTA RCC-208 would accrue to Arcus’s own economics and could influence how investors view upcoming 2026 RCC readouts and longer term revenue potential.

Arcus Biosciences' narrative projects $219.9 million revenue and $41.9 million earnings by 2029. This implies revenues will decline by 2.3% per year and requires an earnings increase of about $410.9 million from -$369.0 million today.

Uncover how Arcus Biosciences' forecasts yield a $35.75 fair value, a 62% upside to its current price.

Exploring Other Perspectives

However, before you get too comfortable, you should know that one underappreciated risk for Arcus investors is...

Some of the most optimistic analysts were already assuming about US$625 million of revenue and a swing to roughly US$80 million of earnings by 2029, so this Bristol Myers Squibb tie up could either reinforce that bullish view or expose how dependent it was on everything going right in RCC, reminding you that reasonable people can look at the same data and reach very different conclusions.

Explore 3 other fair value estimates on Arcus Biosciences - why the stock might be worth just $35.75!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Arcus Biosciences research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Arcus Biosciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Arcus Biosciences' overall financial health at a glance.

Curious About Other Options?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Outshine the giants: these 14 early-stage AI stocks could fund your retirement.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Find 47 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.